L
Lixte Biotechnology Holdings, Inc. (LIXT)
NGM – Real Time Price. Currency in USD
7.21
+7.21 (0.00%)
Market open: Jul 2, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
7.21
+7.21 (0.00%)
Market open: Jul 2, 2026, 4:00 PM EDT
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-07-17 | PRE 14A | formpre14a.htm |
| 2026-07-10 | 8-K | form8-k.htm |
| 2026-07-02 | 8-K | form8-k.htm |
| 2026-06-18 | 8-K | form8-k.htm |
| 2026-06-16 | 8-K | form8-k.htm |
| 2026-06-04 | 8-K | form8-k.htm |
| 2026-06-01 | 8-K | form8-k.htm |
| 2026-05-14 | 10-Q | form10-q.htm |
| 2026-04-17 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |